Table 3: Treatment patterns among NOACs and warfarin cohorts.
| – |
Overall Cohort |
Apixaban Cohort |
Dabigatran Cohort |
Rivaroxaban Cohort |
Warfarin Cohort |
| N/Mean |
%/SD |
N/Mean |
%/SD |
N/Mean |
%/SD |
N/Mean |
%/SD |
N/Mean |
%/SD |
| Overall Study Population |
468 |
100.0% |
147 |
31.4% |
98 |
20.9% |
156 |
33.3% |
67 |
14.3% |
| Baseline Medication Use |
|
|
|
|
|
|
|
|
|
|
| Antiplatelet Drugs |
178 |
38.0% |
68 |
46.3% |
26 |
26.5% |
51 |
32.7% |
33 |
49.3% |
| Other Anticoagulants |
180 |
38.5% |
71 |
48.3% |
29 |
29.6% |
49 |
31.4% |
31 |
46.3% |
| Angiotensin Receptor Blockers |
151 |
32.3% |
48 |
32.7% |
37 |
37.8% |
51 |
32.7% |
15 |
22.4% |
| Statins |
237 |
50.6% |
81 |
55.1% |
42 |
42.9% |
75 |
48.1% |
39 |
58.2% |
| Aspirin |
154 |
32.9% |
56 |
38.1% |
25 |
25.5% |
46 |
29.5% |
27 |
40.3% |
| Aspirin Dose (mean, in mg) |
102.7 |
45.50 |
99.6 |
24.10 |
104.6 |
47.10 |
97.9 |
33.80 |
115.2 |
82.00 |
| 75 mg |
30 |
19.5% |
8 |
14.3% |
7 |
28.0% |
9 |
19.6% |
6 |
22.2% |
| 81 mg |
30 |
19.5% |
11 |
19.6% |
3 |
12.0% |
10 |
21.7% |
6 |
22.2% |
| 100 mg |
112 |
72.7% |
44 |
78.6% |
18 |
72.0% |
30 |
65.2% |
20 |
74.1% |
| 300 mg |
9 |
5.8% |
3 |
5.4% |
2 |
8.0% |
2 |
4.3% |
2 |
7.4% |
| 500 mg |
1 |
0.6% |
- |
0.0% |
- |
0.0% |
- |
0.0% |
1 |
3.7% |
| Index Dose (in mg) * |
|
|
|
|
|
|
|
|
|
|
| Standard dose |
262 |
65.3% |
107 |
72.8% |
42 |
42.9% |
113 |
72.4% |
|
|
| Lower dose |
136 |
33.9% |
40 |
27.2% |
56 |
57.1% |
40 |
25.6% |
|
|
| Other dose |
3 |
0.7% |
|
|
|
|
3 |
1.9% |
|
|
| Follow-up (mean, in days) |
334.2 |
263.6 |
280.4 |
240.0 |
363.2 |
271.0 |
374.6 |
278.1 |
315.8 |
250.5 |
| Median |
282.0 |
|
225.0 |
|
301.0 |
|
315.0 |
|
242.0 |
|
SD: Standard Deviation
* Apixaban (Standard dose: 5 mg; Lower dose: 2.5 mg); Dabigatran (Standard dose: 150 mg; Lower dose: 75 or 110 mg); Rivaroxaban (Standard dose: 20 mg; Lower dose: 10 or 15 mg; Other dose: 10 and 15 mg OR 15 and 20 mg on the same day); Warfarin had variable dosing.